Clinical trial
CATIE- Schizophrenia Trial
NCT00014001 · National Institute of Mental Health (NIMH), NIH · Completed
Key facts
| NCT number | NCT00014001 |
|---|---|
| Title | CATIE- Schizophrenia Trial |
| Official title | Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial) |
| Lead sponsor | National Institute of Mental Health (NIMH), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate |
| Enrollment | 1,600 |
| Start date | Dec 1, 2000 |
| Completion | Dec 1, 2004 |
| First posted | Apr 9, 2001 |
| Last update posted | Jun 17, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: